Preclinical Efficacy of Anecortave Acetate
-
Add time:07/19/2019 Source:sciencedirect.com
Anecortave acetate is a unique ocular angiostatic cortisene that has broad-based anti-angiogenic activity in 14 different preclinical models of neovascularization, across multiple species and inducers of neovascularization. Anecortave acetate is being tested clinically for inhibition of choroidal neovascularization associated with age-related macular degeneration.
We also recommend Trading Suppliers and Manufacturers of ANECORTAVE ACETATE RELATED COMPOUND A (20 MG) (9(11 )-DEHYDROCORTISOL) (cas 10184-70-0). Pls Click Website Link as below: cas 10184-70-0 suppliers
Prev:Characterization of phosphonate-based antiscalants used in drinking water treatment plants by anion-exchange chromatography coupled to electrospray ionization time-of-flight mass spectrometry and inductively coupled plasma mass spectrometry
Next:Pharmacokinetics and Metabolism of Anecortave Acetate in Animals and Humans) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Anterior Juxtascleral Delivery of Anecortave Acetate in Eyes with Primary Open-Angle Glaucoma: A Pilot Investigation07/23/2019
- Anecortave Acetate (15 Milligrams) versus Photodynamic Therapy for Treatment of Subfoveal Neovascularization in Age-Related Macular Degeneration07/22/2019
- Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration07/20/2019
- Pharmacokinetics and Metabolism of Anecortave Acetate in Animals and Humans07/21/2019
